

Bölüm 23

Perinatal Depresyon



Ahmet Alp KARAKAŞLI¹
Sertaç AK²

Giriş

Perinatal dönemde depresyon, yalnızca bir kadının kendi yaşam kalitesini ve annelik deneyimini değil aynı zamanda bebeğini, diğer çocuklarını, eşini ve etrafındaki herkesi etkileyen ağır bir tablodur. Tibbi yardım veya tedavi olmadığında preeklampsı, düşük doğum ağırlığı veya intihar gibi ağır sonuçlara neden olabilmektedir.

Perinatal dönemde depresyon belirtilerinin gözden kaçırılmaması için kadın hastalıkları ve doğum alanında çalışan sağlık personelinin konuya ilgili güncel bilgiye sahip olması oldukça önemlidir.

Tanım olarak perinatal depresyon; gebelikte (antenatal depresyon) veya doğum sonrası ilk 12 ay içinde (postpartum depresyon) ortaya çıkan depresyon dönemlerini ifade etmektedir. Postpartum dönemin ifade ettiği zaman aralığı için doğumdan sonraki ilk dört hafta ile ilk on iki ay arasında farklı tanımlar bulunmaktadır [1, 2].

Epidemiyoloji

Depresyon dünya genelinde yaklaşık 300 milyon kişiyi etkileyen yaygın bir pszichiatrik bozukluktur [3]. Depresyon, aynı zamanda yeti yitimine yol açan en önemli hastalıkların da başında gelmektedir [4]. Major depresyon kadınlarda erkeklerde göre daha yaygın olarak görülmektedir. Kadınlarda major depresyon

¹ Dr. Öğr. Üyesi, Hıtit Üniversitesi Tıp Fakültesi Ruh Sağlığı ve Hastalıkları AD, alpkarakasli@hotmail.com

² Doç. Dr. Hacettepe Üniversitesi Tıp Fakültesi Ruh Sağlığı ve Hastalıkları AD, ?



Kaynaklar

1. Dünya Sağlık Örgütü. Depression and other common mental disorders global health estimates, 2017: <https://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf> (08 Eylül 2019)
2. Liu Q, He H, Yang J, Feng X, Zhao F ve Lyu J. Changes in the global burden of depression from 1990 to 2017: Findings from the Global Burden of Disease study. *Journal of psychiatric research*, 2019.
3. Gavin NI, Gaynes BN, Lohr KN, Meltzer-Brody S, Gartlehner G ve Swinson T. Perinatal depression: a systematic review of prevalence and incidence. *Obstetrics & Gynecology*, 2005; 106(5): 1071-1083.
4. Inandi T, Elci OC, Ozturk A, Egri M, Polat A ve Sahin TK. Risk factors for depression in postnatal first year, in eastern Turkey. *International journal of epidemiology*, 2002; 31(6): 1201-1207.
5. Inandi T, Bugdayci R, Dundar P, Sumer H ve Sasmaz T. Risk factors for depression in the first postnatal year. *Social psychiatry and psychiatric epidemiology*, 2005; 40(9): 725-730.
6. Dindar I ve Erdogan S. Screening of Turkish women for postpartum depression within the first postpartum year: the risk profile of a community sample. *Public Health Nursing*, 2007; 24(2): 176-183.
7. Yağmur Y ve Ulukoca N. Social support and postpartum depression in low-socioeconomic level postpartum women in Eastern Turkey. *International journal of public health*, 2010; 55(6): 543-549.
8. Gümüş AB, Keskin G, Alp N, Özyar S ve Karsa A. Postpartum Depresyon Yaygınlığı ve İlişkili Değişkenler. *Yeni Symposium*, 2012; 50(3):145-154.
9. Karakaş NM, Güneş G ve Sarıbüyük M. Battalgazi'de postpartum depresyon riski ve etkili faktörler. *İnönü Üniversitesi Sağlık Hizmetleri Meslek Yüksek Okulu Dergisi*, 2010; 2(1): 1-12.
10. Viktorin A, Meltzer-Brody S, Kuja-Halkola R, Sullivan PF, Landén M, Lichtenstein P ve ark. Heritability of perinatal depression and genetic overlap with nonperinatal depression. *American Journal of Psychiatry*, 2015; 173(2): 158-165.
11. Pinsonneault JK, Sullivan D, Sadee W, Soares CN, Hampson E ve Steiner M. Association study of the estrogen receptor gene ESR1 with postpartum depression—a pilot study. *Archives of women's mental health*, 2013; 16(6): 499-509.
12. Quintivano J, Arad M, Gould TD, Payne JL ve Kaminsky ZA. Antenatal prediction of postpartum depression with blood DNA methylation biomarkers. *Molecular psychiatry*, 2014; 19(5): 560.
13. Bell AF, Carter C, Steer CD, Golding J, Davis JM, Steffen AD ve ark. Interaction between oxytocin receptor DNA methylation and genotype is associated with risk of postpartum depression in women without depression in pregnancy. *Frontiers in genetics*, 2015; 6: 243.
14. Koren G, Finkelstein Y, Matsui D ve Berkovich M. Diagnosis ve management of poor neonatal adaptation syndrome in newborns exposed in utero to selective serotonin/norepinephrine reuptake inhibitors. *Journal of Obstetrics and Gynaecology Canada*, 2009; 31(4): 348-350.
15. Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S ve Katon WJ. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. *Archives of general psychiatry*, 2010; 67(10): 1012-1024.
16. Field T. Postpartum depression effects on early interactions, parenting, and safety practices: a review. *Infant Behavior and Development*, 2010; 33(1): 1-6.



17. Sutter-Dallay AL, Murray L, Dequae-Merchadou L, Glatigny-Dallay E, Bourgeois ML ve Verdoux H. A prospective longitudinal study of the impact of early postnatal vs. chronic maternal depressive symptoms on child development. *European Psychiatry*, 2011; 26(8): 484-489.
18. Verbeek T, Bockting CL, van Pampus MG, Ormel J, Meijer JL, Hartman CA ve ark. Postpartum depression predicts offspring mental health problems in adolescence independently of parental lifetime psychopathology. *Journal of affective disorders*, 2012; 136(3): 948-954.
19. Committee on Psychosocial Aspects of Child Family Health. Incorporating recognition and management of perinatal and postpartum depression into pediatric practice. *Pediatrics*, 2010; 126(5): 1032-1039.
20. American College of Obstetricians and Gynecologists. ACOG committee opinion no. 757: Screening for perinatal depression. *Obstetrics & Gynecology*, 2018; 132:e208-e212.
21. U.S. Preventive Services Task Force. Screening for Depression in Adults: An Updated Systematic Evidence Review for the US Preventive Services Task Force. 2016.
22. National Institute for Health and Care Excellence. Antenatal and postnatal mental health: clinical management and service guidance (CG192), 2014. <https://www.nice.org.uk/guidance/cg192/resources/antenatal-and-postnatal-mental-health-clinical-management-and-service-guidance-pdf-35109869806789> (15 Ağustos 2019).
23. Engindeniz A, Kuey L and Kultur S. Validity and reliability of Turkish version of Edinburgh Postnatal Depression Scale. In: Book of Annual Meeting of Psychiatric Association of Turkey. Ankara:Turkish Psychiatric Association Press, 1996.
24. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Association, 2013.
25. Gentile S. Tricyclic antidepressants in pregnancy and puerperium. Expert opinion on drug safety, 2014; 13(2): 207-225.
26. Hendrick V ve Altshuler L. Management of major depression during pregnancy. *American Journal of Psychiatry*, 2002; 159(10): 1667-1673.
27. Gao S-Y, Wu Q-J, Sun C, Zhang T-N, Shen Z-Q, Liu C-X ve ark. Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births. *BMC medicine*, 2018; 16(1): 205.
28. Malm H, Brown AS, Gissler M, Gyllenberg D, Hinkka-Yli-Salomäki S, McKeague IW ve ark. Gestational exposure to selective serotonin reuptake inhibitors and offspring psychiatric disorders: a national register-based study. *Journal of the American Academy of Child & Adolescent Psychiatry*, 2016; 55(5): 359-366.
29. Almeida ND, Basso O, Abrahamowicz M, Gagnon R ve Tamblyn R. Risk of miscarriage in women receiving antidepressants in early pregnancy, correcting for induced abortions. *Epidemiology*, 2016; 27(4): 538-546.
30. Ross LE, Grigoriadis S, Mamisashvili L, VonderPorten EH, Roerecke M, Rehm J ve ark. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. *JAMA psychiatry*, 2013; 70(4): 436-443.
31. Simon GE, Cunningham ML ve Davis RL. Outcomes of prenatal antidepressant exposure. *American Journal of Psychiatry*, 2002; 159(12): 2055-2061.
32. Palmsten K, Huybrechts KF, Michels KB, Williams PL, Mogun H, Setoguchi S ve ark. Antidepressant use and risk for preeclampsia. *Epidemiology (Cambridge, Mass.)*, 2013; 24(5): 682.



ANTENATAL BAKIM

33. Malm H, Sourander A, Gissler M, Gyllenberg D, Hinkka-Yli-Salomäki S, McKeague IW ve ark. Pregnancy complications following prenatal exposure to SSRIs or maternal psychiatric disorders: results from population-based national register data. *American Journal of Psychiatry*, 2015; 172(12): 1224-1232.
34. Grigoriadis S, VonderPorten EH, Mamisashvili L, Tomlinson G, Dennis CL, Koren G ve ark. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. *Bmj*, 2014; 348: f6932.
35. Nörby U, Forsberg L, Wide K, Sjörs G, Winbladh B ve Källén K. Neonatal morbidity after maternal use of antidepressant drugs during pregnancy. *Pediatrics*, 2016; 138(5): e20160181.
36. Huybrechts KF, Bateman BT, Palmsten K, Desai RJ, Patorno E, Gopalakrishnan C ve ark. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. *Jama*, 2015; 313(21): 2142-2151.
37. Sørensen MJ, Grønborg TK, Christensen J, Parner ET, Vestergaard M, Schendel D ve ark. Antidepressant exposure in pregnancy and risk of autism spectrum disorders. *Clinical epidemiology*, 2013; 5: 449.
38. Oystein Berle J ve Spigset O. Antidepressant use during breastfeeding. *Current women's health reviews*, 2011; 7(1): 28-34.